Fever for days: A challenging case of dalbavancin-induced fever
Dalbavancin is a novel long acting lipoglycopeptide antibiotic with a favorable safety profile approved for treating Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by Gram-positive organisms. Given its long half-life, a two-dose regimen can provide effective systemic therapy for...
Saved in:
| Main Authors: | Mohamed A. Almahal, Claire Wan, Benjamin Albrecht, Sarah Green, Ahmed Babiker |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | IDCases |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214250924002142 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Strategies to Stabilize Dalbavancin in Aqueous Solutions; Section-2: The Effects of 2 Hydroxypropyl-β-Cyclodextrin and Acetate Buffer with and Without Divalent Metal Ions
by: Sardar M. Jakaria, et al.
Published: (2024-11-01) -
Using Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) in Obese Patients: A Real-Life, Single-Center Observational Study
by: Alessandra Oliva, et al.
Published: (2025-01-01) -
Exploratory analysis of long-term suppressive therapy with dalbavancin in ventricular assist device infections caused by Staphylococcus aureus
by: Benedict Morath, et al.
Published: (2025-05-01) -
Multidose Dalbavancin Population Pharmacokinetic Analysis for Prolonged Target Attainment in Patients Requiring Long-Term Treatment
by: Giammarco Baiardi, et al.
Published: (2025-02-01) -
Safety and Efficacy of Dalbavancin in Real Life: Retrospective Analysis of a Large Monocentric Case Series of Patients Treated for Skin/Soft Tissue and Other Difficult-to-Treat Infections
by: Giustino Parruti, et al.
Published: (2024-11-01)